Evidence map›Paper›PMID 36214853›Full record

SynthesisAnnals of hematology2022

Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature.

Adeel Masood, Qamar Iqbal, Hamid Ehsan, James A Davis, Doris K Hansen, Hamza Hashmi

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Annals of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Adeel MasoodUniversity of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. adeelmasood100@gmail.com.ORCID http://orcid.org/0000-0001-7085-777X
Qamar IqbalInternal Medicine - Tidal Health Peninsula Regional, 100 East Carroll Street, Salisbury, MD, 21801, USA.
Hamid EhsanLevine Cancer Institute/Atrium Health, 1021 Morehead Medical Drive, Charlotte, NC, 28262, USA.
James A DavisHematology/Oncology, Medical University of South Carolina, 171 Ashley Ave, Charleston, SC, 29425, USA.
Doris K HansenDepartment of Blood and Marrow Transplant and Cellular Immunotherapy (BMT CI), H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Drive, Tampa, FL, 33612, USA.
Hamza HashmiHematology/Oncology, Medical University of South Carolina, 171 Ashley Ave, Charleston, SC, 29425, USA.
Medical University of South Carolina · USLevine Cancer Institute · USMoffitt Cancer Center · USPeninsula Regional Medical Center · USThe University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the incorporation of novel agents in earlier lines of therapy, an increasing number of multiple myeloma patients are refractory to traditional classes of drugs. Selinexor in combination with dexamethasone has emerged as a viable option for heavily pretreated triple-class relapsed and refractory multiple myeloma (RRMM). In this systematic review, we analyzed available literature on the role of selinexor in RRMM. The Boston trial demonstrated that selinexor when combined with dexamethasone and bortezomib is associated with a better depth and duration of response without excessive toxicity, compared with bortezomib and dexamethasone alone. Similarly, selinexor in combination with carfilzomib and dexamethasone was found to have a durable response and tolerable safety profile in both carfilzomib-naive and carfilzomib refractory RRMM patients. Selinexor in combination with IMiDs (lenalidomide and pomalidomide) as well as CD38 monoclonal antibodies (daratumumab) also have promising results. Selinexor combination therapy is both safe and effective for patients with pretreated RRMM.

Indexed as

Multiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsBortezomibDexamethasoneHumansHydrazinesNeoplasm Recurrence, LocalTriazolesBortezomibDexamethasoneHydrazinesselinexorTriazolesImmunomodulatory agentsMonoclonal antibodiesMultiple myelomaProteasome inhibitorsRelapsed/RefractorySelinexor

Identifiers

PMID36214853
OpenAlexW4303986386

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.